




Prostatype Genomics



Investor presentation
Fredrik Persson, CEO
April 2023

Why invest in Prostatype Genomics?

- **Clear clinical need for more accurate prognostic biomarkers**
- **Global annual billion dollar market**
- **Ready and externally validated product on the market without technical risk – more than 1/3 of the patients are reclassified to the correct risk group**
- **Complement to existing clinical pathway at urologist and laboratory. Attractive and highly profitable business model.**
- **Low financial and commercial risk**

~ 1 300 000

Newly diagnosed prostate
cancer patients per year

~ 845 000

Newly diagnosed patients in
low- and intermediate risk
segment per year

~ 5 000 000

Diagnosed but not radically
treated patients

~ 5,5 billion

SEK/year

Estimated market potential

Prostatype®
Market size

This is Prostatype®




Laboratory kit
PCR



P-score
algorithm




Database prostate
cancer patients




- Complete test system that can be used at any laboratory
- Easy to use

Prostate cancer

- Clinical pathway including Prostatype®



What is the risk of dying from prostate cancer for a patient diagnosed with low or intermediate risk prostate cancer without radical treatment?



Obvious clinical need to better classify the patients to the relevant risk group and to confirm patients classified into certain risk group

*Hamdy EC et al, 2016, Klotz et al, 2015, Stattin et al, 2010


** Svensk urologisk förening, Nationell kvalitetsrapport, 2019

What clinical need does Prostatype[®] fulfill?

Diagnostic tools used today:



PSA (+MRI)



T-stage + biopsy



Gleason scale




Cancer confirmed but if and how should the patient be radically treated?

- Today's conventional tools are old, blunt and highly subjective
 - Uncertainty results in over treatment


Prostate cancer

- Clinical pathway including Prostatype®




- Today's tools

+



- Same biopsy as used in diagnosis phase
- No additional interventions needed

=



- Confirms prostate cancer
- Stratifies the correct patient to the correct risk group: low, intermediate or high risk
- Supports and guides the correct treatment decision for the individual patient

- Complement to today's used diagnostic tools
- More and more patients expects an individual treatment decision
- Prostatype® provides a more accurate answer to the aggressiveness of the cancer
- Fewer patients have to undergo painful overtreatment with a high rate of life long side effects
 - "False negative" patients are detected


Clinical performance - external validation

Of all diagnosed pca-patients in County Council of Skåne 2008-2010 (316 patients), a new examination was performed of all biopsies using Prostatype. Prostatype changed the classification for 35% of the patients which would have altered the treatment decision.

Original risk classification	ISUP/Gleason Score		Patients	%	PCA-death	Secondary metastasis
	Prostatype P-Score					
Low	Low		10	77%		
	Intermediate		3	23%		
	High		0	0%		
Intermediate	Low		40	36,7%		
	Intermediate		60	55%		1
	High		9	8,3%		
High	Low		13	10,5%		
	Intermediate		39	31,5%		2
	High		72	58%	16	21
Lokally advanced	Low		1	1,4%		
	Intermediate		4	5,8%		
	High		64	92,8%	16	22


Prostatype validation study University Hospital of Lund, Göran Ahlgren et al, 2023.
doi: [10.1002/pros.24530](https://doi.org/10.1002/pros.24530)

=




Prostatype Genomics

- market and development journey




Only 150 urologists globally needed to reach break-even



A promising start and
not that far away...

* All healthcare centres/clinics having completed internal validation have expressed that they are to implement Prostatype in clinical routine


Prostatype Genomics - Business model EMEA



Prostatype[®] gross margin in EMEA: 98,7- 99,3 %

Prostatype Genomics Inc.

- Business model USA



- Prognostic biomarkers in clinical routine for more than 10 years
- Reimbursement in place from Medicare as well as from private insurance companies
- Reimbursement level: 3 879 USD per patient/test
- Significant interest regarding Prostatypes USP:s:
 - Genetic signature from embryonal stem cells – unique biomarker
 - All CLIA-approved labs can perform the test – simple and highly profitable
- High interest for Prostatype Genomics business model from physicians as well as from commercial partners
- FDA-approval not needed for commercialisation
 - Limited commercial risk and cost for Prostatype Genomics

**Exciting
opportunities
in the US**

Upcoming rights issue

Time plan:

- Last trading day including right to obtain subscription rights: 21st April 2023
- Record date (avstämningsdag): 25th of April 2023
- Subscription period: 27th of April – 11th of May 2023
- Trading with subscription rights: 27th of April – 8th May 2023

Terms & conditions:

- One (1) existing share in Prostatype Genomics 25th April 2023 entitles to one (1) subscription right. One (1) subscription right entitles for subscription of six (6) newly issued shares
- Subscription price 0,25 SEK per share
- Total emission size: 34,3 MSEK, guaranteed at 70%

Use of funds?

- Validation studies USA
- Investments in sales and regulatory activities, USA
- Expansion of commercial organisation in USA and Europe
- Validation studies in Sweden, Spain, Taiwan, France
- Reinforcement of working capital, ongoing business

Why invest in Prostatype Genomics?

- Clear clinical need for more accurate prognostic biomarkers
- Global annual billion dollar market
- Ready and externally validated product on the market without technical risk – more than 1/3 of the patients are reclassified to the right risk group
- Complement to existing clinical pathway at urologist and laboratory Attractive and highly profitable business model
- Low financial and commercial risk